Patient Satisfaction with Once-Daily Single-Tablet Darunavir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide (DRV/c/FTC/TAF): A Real-World Study of Patient Self-Reported Outcomes in HIV-1–Diagnosed Adults

References

• Centers for Disease Control and Prevention. Diagnoses of HIV infection in the United States and dependent areas, 2018 (Updated). HIV Surveillance Report 2018 (Updated). Vol. 31; 2018.
   Google Scholar
• Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV; 2021. Available from: https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/AdultandAdolescentGL.pdf. Accessed July 15, 2021.
   Google Scholar
• Al-Dakkak I, Patel S, McCann E, Gadkari A, Prajapati G, Maiese EM. The impact of specific HIV treatment-related adverse events on adherence to antiretroviral therapy: a systematic review and meta-analysis. AIDS Care. 2013;25(4):400–414. doi:10.1080/09540121.2012.712667
   PubMed Web of Science ®Google Scholar
• McGowan JA, Sherr L, Rodger AJ, et al. Age, time living with diagnosed HIV infection, and self-rated health. HIV Med. 2017;18(2):89–103. doi:10.1111/hiv.12398
   PubMed Web of Science ®Google Scholar
• Snyder CF, Jensen RE, Segal JB, Wu AW. Patient-reported outcomes (PROs): putting the patient perspective in patient-centered outcomes research. Med Care. 2013;51(8 Suppl 3):S73–79. doi:10.1097/MLR.0b013e31829b1d84
   PubMed Web of Science ®Google Scholar
• Weldring T, Smith SM. Patient-reported outcomes (PROs) and patient-reported outcome measures (PROMs). Health Serv Insights. 2013;6:61–68. doi:10.4137/HSI.S11093
   PubMedGoogle Scholar
• Shubber Z, Mills EJ, Nachega JB, et al. Patient-reported barriers to adherence to antiretroviral therapy: a systematic review and meta-analysis. PLoS Med. 2016;13(11):e1002183. doi:10.1371/journal.pmed.1002183
   PubMed Web of Science ®Google Scholar
• Orkin C, Eron JJ, Rockstroh J, et al. Week 96 results of a phase 3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naive HIV-1 patients. AIDS. 2020;34(5):707–718. doi:10.1097/QAD.0000000000002463
   PubMed Web of Science ®Google Scholar
• Eron JJ, Orkin C, Cunningham D, et al. Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1. Antiviral Res. 2019;170:104543. doi:10.1016/j.antiviral.2019.104543
   PubMed Web of Science ®Google Scholar
• Huhn GD, Crofoot G, Ramgopal M, et al. Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in a rapid initiation model of care for HIV-1 infection: primary analysis of the DIAMOND study. Clin Infect Dis. 2020;71(12):3110–3117. doi:10.1093/cid/ciz1213
   PubMed Web of Science ®Google Scholar
• Jacinto J, Varriale P, Pain E, Lysandropoulos A, Esquenazi A. Patient perspectives on the therapeutic profile of botulinum neurotoxin type a in spasticity. Front Neurol. 2020;11:388. doi:10.3389/fneur.2020.00388
   PubMed Web of Science ®Google Scholar
• Lambert J, Chekroun M, Gilet H, Acquadro C, Arnould B. Assessing patients’ acceptance of their medication to reveal unmet needs: results from a large multi-diseases study using a patient online community. Health Qual Life Outcomes. 2018;16(1):134. doi:10.1186/s12955-018-0962-3
   PubMed Web of Science ®Google Scholar
• Woodcock A, Bradley C. Validation of the HIV treatment satisfaction questionnaire (HIVTSQ). Qual Life Res. 2001;10(6):517–531. doi:10.1023/A:1013050904635
   PubMed Web of Science ®Google Scholar
• Justice AC, Holmes W, Gifford AL, et al. Development and validation of a self-completed HIV symptom index. J Clin Epidemiol. 2001;54(Suppl 1):S77–90. doi:10.1016/S0895-4356(01)00449-8
   PubMed Web of Science ®Google Scholar
• Marc LG, Wang MM, Testa MA. Psychometric evaluation of the HIV symptom distress scale. AIDS Care. 2012;24(11):1432–1441. doi:10.1080/09540121.2012.656567
   PubMed Web of Science ®Google Scholar
• Casado JL, Marin A, Romero V, et al. The influence of patient beliefs and treatment satisfaction on the discontinuation of current first-line antiretroviral regimens. HIV Med. 2016;17(1):46–55. doi:10.1111/hiv.12280
   PubMed Web of Science ®Google Scholar
• Mtambo A, Harris M, Toy J, et al. Evaluation of treatment tolerability, satisfaction and laboratory parameters in HIV+ patients switching from ritonavir capsule to tablet formulation. Curr HIV Res. 2013;11(3):231–237. doi:10.2174/1570162X11311030008
   PubMed Web of Science ®Google Scholar
• Jordan J, Cahn P, Goebel F, Matheron S, Bradley C, Woodcock A. Abacavir compared to protease inhibitors as part of HAART regimens for treatment of HIV infection: patient satisfaction and implications for adherence. AIDS Patient Care STDS. 2005;19(1):9–18. doi:10.1089/apc.2005.19.9
   PubMed Web of Science ®Google Scholar
• Cohen CJ, Meyers JL, Davis KL. Association between daily antiretroviral pill burden and treatment adherence, hospitalisation risk, and other healthcare utilisation and costs in a US medicaid population with HIV. BMJ Open. 2013;3(8):e003028. doi:10.1136/bmjopen-2013-003028
   PubMed Web of Science ®Google Scholar
• Clay PG, Yuet WC, Moecklinghoff CH, et al. A meta-analysis comparing 48-week treatment outcomes of single and multi-tablet antiretroviral regimens for the treatment of people living with HIV. AIDS Res Ther. 2018;15(1):17. doi:10.1186/s12981-018-0204-0
   PubMed Web of Science ®Google Scholar
• Antinori A, Cossu MV, Menzaghi B, et al. Patient-reported outcomes in an observational cohort of HIV-1-infected adults on darunavir/cobicistat-based regimens: beyond viral suppression. Patient. 2020;13(3):375–387. doi:10.1007/s40271-020-00413-y
   PubMedGoogle Scholar
• Palella F, Fisher M, Tebas P, et al. SPIRIT: switching to rilpivirine/emtricitabine/tenofovir DF single-tablet regimen from boosted protease inhibitor maintains HIV-1 suppression through week 48. Poster presented at: American Conference for the Treatment of HIV (ACTHIV); March 21–23; 2013; Denver, CO.
   Google Scholar
• Mills A, Garner W, Pozniak A, et al. Patient-reported symptoms over 48 weeks in a randomized, open-label, phase IIIb non-inferiority trial of adults with HIV switching to co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir DF versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir DF. Patient. 2015;8(4):359–371. doi:10.1007/s40271-015-0129-9
   PubMedGoogle Scholar
• Gathe J, Arribas JR, Van Lunzen J, et al. Patient-reported symptoms over 48 weeks in a randomized, open-label, phase 3b non-inferiority trial of adults with HIV switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir DF versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir DF. Patient. 2015;8(5):445–454. doi:10.1007/s40271-015-0137-9
   PubMedGoogle Scholar
• van Lunzen J, Antinori A, Cohen CJ, et al. Rilpivirine vs. efavirenz-based single-tablet regimens in treatment-naive adults: week 96 efficacy and safety from a randomized phase 3b study. AIDS. 2016;30(2):251–259. doi:10.1097/QAD.0000000000000911
   PubMed Web of Science ®Google Scholar
• Brunetta J, Moreno Guillen S, Antinori A, et al. Patient-reported outcomes after a switch to a single-tablet regimen of rilpivirine, emtricitabine, and tenofovir DF in HIV-1-positive, virologically suppressed individuals: additional findings from a randomized, open-label, 48-week trial. Patient. 2015;8(3):257–267. doi:10.1007/s40271-015-0123-2
   PubMedGoogle Scholar
• Wohl D, Clarke A, Maggiolo F, et al. Patient-reported symptoms over 48 weeks among participants in randomized, double-blind, Phase III non-inferiority trials of adults with HIV on co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus co-formulated Abacavir, dolutegravir, and lamivudine. Patient. 2018;11(5):561–573. doi:10.1007/s40271-018-0322-8
   PubMedGoogle Scholar
• Quatremere G, Guiguet M, Girardi P, et al. How are women living with HIV in France coping with their perceived side effects of antiretroviral therapy? Results from the EVE study. PLoS One. 2017;12(3):e0173338. doi:10.1371/journal.pone.0173338
   PubMed Web of Science ®Google Scholar
• ElZarrad MK, Corrigan-Curay J. The US Food and Drug Administration’s real-world evidence framework: a commitment for engagement and transparency on real-world evidence. Clin Pharmacol Ther. 2019;106(1):33–35. doi:10.1002/cpt.1389
   PubMed Web of Science ®Google Scholar
• Huhn GD, Tebas P, Gallant J, et al. A randomized, open-label trial to evaluate switching to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide plus darunavir in treatment-experienced HIV-1-infected adults. J Acquir Immune Defic Syndr. 2017;74(2):193–200. doi:10.1097/QAI.0000000000001193
   PubMed Web of Science ®Google Scholar
• Lazarus JV, Safreed-Harmon K, Barton SE, et al. Beyond viral suppression of HIV - the new quality of life frontier. BMC Med. 2016;14(1):94. doi:10.1186/s12916-016-0640-4
   PubMed Web of Science ®Google Scholar
• Joint United National Programme on HIV/AIDS. 90-90-90: an ambitious treatment target to help end the AIDS epidemic; 2014. Available from: https://www.unaids.org/sites/default/files/media_asset/90-90-90_en.pdf. Accessed April 29, 2021.
   Google Scholar
• Centers for Disease Control and Prevention. Diagnoses of HIV infection in the United States and dependent areas 2019: national profile. HIV Surveillance Report 2019. Vol. 32; 2021.
   Google Scholar
• Murray M, Antela A, Mills A, et al. Patient-reported outcomes in ATLAS and FLAIR participants on long-acting regimens of cabotegravir and rilpivirine over 48 weeks. AIDS Behav. 2020;24(12):3533–3544. doi:10.1007/s10461-020-02929-8
   PubMed Web of Science ®Google Scholar
• Murray M, Pulido F, Mills A, et al. Patient-reported tolerability and acceptability of cabotegravir + rilpivirine long-acting injections for the treatment of HIV-1 infection: 96-week results from the randomized LATTE-2 study. HIV Res Clin Pract. 2019;20(4–5):111–122. doi:10.1080/25787489.2019.1661696
   PubMed Web of Science ®Google Scholar
• Czeisler ME, Marynak K, Clarke KEN, et al. Delay or avoidance of medical care because of COVID-19-related concerns - United States, June 2020. MMWR Morb Mortal Wkly Rep. 2020;69(36):1250–1257. doi:10.15585/mmwr.mm6936a4
   PubMed Web of Science ®Google Scholar
• Hartnett KP, Kite-Powell A, DeVies J, et al. Impact of the COVID-19 pandemic on emergency department visits - United States, January 1, 2019–May 30, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(23):699–704. doi:10.15585/mmwr.mm6923e1
   PubMed Web of Science ®Google Scholar